Tedatioxetine

From Wikipedia, the free encyclopedia
Tedatioxetine
Systematic (IUPAC) name
4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
Clinical data
Legal status Investigational
Identifiers
CAS number 508233-95-2 YesY
ATC code None
PubChem CID 9878913
ChemSpider 8054590 YesY
KEGG D10170 N
Synonyms Lu AA24530; Lu-AA-24530
Chemical data
Formula C18H21NS 
Mol. mass 283.43 g/mol
 N (what is this?)  (verify)

Tedatioxetine (Lu AA24530) is an antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD).[1][2] Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and in addition as a 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.<ref name="urlUSPTO Applications - Publication No. 20100144788 - "4- [2- (4-METHYLPHENYLSULFANYD-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION"">"SureChem - Document - USPTO Applications - Publication No. 20100144788". Retrieved 9 October 2012. </ref>[3][4][5][6] It is currently in Phase II of clinical trials.[1]

See also

References

  1. ↑ 1.0 1.1 "Pipeline of Lundbeck". Retrieved 25 August 2013. 
  2. ↑ "Search of: Lu AA24530 - List Results - ClinicalTrials.gov". 
  3. ↑ Stephen M. Stahl (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011. 
  4. ↑ Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011. 
  5. ↑ "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech". 
  6. ↑ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net". 

External links

Anxiolytics (N05B)
GABAA
PAMs
non-N05B
α2δ VDCC Blockers
5-HT1A Agonists
H1 Antagonists
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Antidepressants
Others

M: PSO/PSI

mepr

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc (eval/thrp), drug (N5A/5B/5C/6A/6B/6D)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.